Insmed, Inc. (NASDAQ:INSM) Shares Sold by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust lowered its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 11.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 353,831 shares of the biopharmaceutical company's stock after selling 46,793 shares during the period. Insmed makes up 1.9% of Emerald Mutual Fund Advisers Trust's portfolio, making the stock its 6th biggest position. Emerald Mutual Fund Advisers Trust owned about 0.19% of Insmed worth $26,994,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. National Bank of Canada FI boosted its stake in Insmed by 9.7% during the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 147 shares during the last quarter. M&T Bank Corp boosted its stake in Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after acquiring an additional 147 shares during the last quarter. Snowden Capital Advisors LLC lifted its position in shares of Insmed by 2.5% in the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after buying an additional 158 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its position in shares of Insmed by 3.7% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,314 shares of the biopharmaceutical company's stock worth $436,000 after buying an additional 225 shares during the last quarter.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total value of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares in the company, valued at $8,352,401.94. This trade represents a 52.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Sara Bonstein sold 57,766 shares of the firm's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $89.12, for a total transaction of $5,148,105.92. Following the completion of the transaction, the chief financial officer owned 103,412 shares of the company's stock, valued at approximately $9,216,077.44. The trade was a 35.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 546,516 shares of company stock worth $48,737,083. 3.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on INSM shares. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insmed in a report on Tuesday, June 10th. The Goldman Sachs Group increased their price objective on shares of Insmed from $100.00 to $112.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Citigroup raised shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. Morgan Stanley increased their price objective on shares of Insmed from $90.00 to $102.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. Finally, Wells Fargo & Company increased their price objective on shares of Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and a consensus target price of $108.07.

Insmed Price Performance

Shares of INSM traded up $1.52 during mid-day trading on Friday, hitting $98.18. The company's stock had a trading volume of 3,244,487 shares, compared to its average volume of 2,292,825. The firm has a 50-day moving average price of $83.40 and a 200 day moving average price of $77.35. The stock has a market capitalization of $18.63 billion, a price-to-earnings ratio of -16.50 and a beta of 0.90. The company has a debt-to-equity ratio of 11.38, a current ratio of 5.86 and a quick ratio of 5.44. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.06) EPS. On average, research analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.